Towards a World Platform for Breast Centers Accreditation: A Global Vision

Union for International Cancer Control



Dr Eduardo Cazap, UICC President

ecazap@uicc.org

2nd International Congress of Breast Disease Centers

EC : Disclosures

- <u>Leadership Position (no honoraria</u>) SLACOM, ASCO, UICC
- Consultant or Advisory Role : Bayer; Schering Pharma
- *Honoraria :* Bayer; Bristol-Myers Squibb ; Fresenius
- <u>Research Funding: Paid to Institution</u>: Poniard Pharmaceuticals ; Daiichi Sankyo Pharma ; Breast Cancer Research Foundation (BCRF)
- I have not relevant disclosures to make related with this presentation











<u>Outline</u>

- Breast cancer in the world
- International harmonization ; chalenges and possibilities. The BHGI example
- Role of leading organizations
- Future possible actions





Breast cancer in the world





Background

 The world is facing a critical health care problem: in the next few decades cancer will become a leading global public health problem disproportionately increasing in low and middle income countries (LMCs). Breast cancer is a critical component of the global cancer problem.

Ref. E. Cazap et al. / The Breast 20 (2011) S1–S2





Introduction Level of analysis

- 1. Physician- patient relationship
- 2. Scientific societies recommendations, guidelines, consensus
- 3. Health care country norms and guidelines
- 4. Global health issues









Brilliant Earth From Space

from: www. geology.com





Human genetic diversity is distributed in gradients among and within continents



Maitland, M. L. et al. J Clin Oncol; 24:2151-2157 2006

Copyright © American Society of Clinical Oncology

US Institute of Medicine

 The US Institute of Medicine report entitled Cancer control opportunities in low- and *middle-income countries* calls "for governments, health professionals, nongovernmental organizations, and others in low- and middle-income countries, with the help of the global health community, to achieve a better understanding of the current and future burden of cancer in low- and middle-income countries and take appropriate and feasible next steps in cancer control". This report makes 18 specific recommendations for worldwide cancer **CONTRO** Ref. Sloan FA, Gelband H, eds. Cancer control opportunities in low-

and middle-income countries. Washington, DC: The National Academies Press, 2007.





Global Health Care Infrastructure



International harmonization ; chalenges and possibilities. The BHGI example





The Breast Health Global Initiative (BHGI): GLOBAL COLLABORATION

MISSION: The Breast Health Global Initiative, a global health alliance of organizations, strives to develop, implement and study evidencebased, economically feasible, and culturally appropriate guidelines for international breast health and cancer control for low- and middleresource countries to improve breast health outcomes.



BREAST HEALTH GLOBAL INITIATIVE

BHGI resource-stratified

guidelines

Output Low-income: Ghana, West Africa

O Middle-income: Latin America www.bhgi.info

BHGI GLOBAL SUMMIT 2007: Budapest: Guideline Implementation



CONSENSUS **STATEMENTS** Early Detection Diagnosis Treatment Health Care Systems 8 Stratified Tables 10 Individual www.bhgi.infc **Manuscripts**

Cancer: 113 (8 suppl), 2008

BHGI GLOBAL SUMMIT 2007: Budapest: Guideline Implementation

HEALTH CARE SYSTEMS

EARLY DETECTION

Level of Patient and Family Education Cancer Care Facility Breast Care Center Primary care provider education re breast Health facility cancer detection, diagnosis and treatment General education regarding primary Operating facility Nursing education re cancer patient Breast healthcare access egrated into existing healthcare prevention of cancer, early detection and Field nurse, midwife or healthcare pro Outpatient care facility self examination management and emotional support triages patients to central facility for diagnosis Pharmacy and treatment infrastructure Development of culturally adapted patient Pathology technician education re tissue Home hospice support and family education services handling and specimen preparation External consultation Trained community worker pathology laboratory Clinical information system Nursing education re-breast cancer diagnosis Breast Center" with clinician, stat Group or one-on-one counseling involving treatment and pt management Health system network On site patient navigator (staff member family and peer support and breast imaging access Imaging facility Limited Imaging technician education re imaging or nurse) facilitates patient triage through Education regarding nutrition and complementary therapies Breast prostheses for technique and quality control diagnosis and treatment Internal pathology laborator mastectomy pts Volunteer recruitment corp to support care Radiation therapy Organization of national volunteer network Centralized referral Education regarding survivorship Specialized nursing oncology training cancer center(s) Multidisciplinary breast program Patient navigation team from each disciplin supports patient "handoff" during key transitions from specialist to specialist to ensure completion of therapy Radiation therapy: low energy I vmphedema education Home care nursing Oncology nurse specialists Enhanor linear accelerator, electrons brachytherapy, treatment planning system Physiotherapist & lymphedema therapist Physician assistants Education regarding home care On-site cytopathologist Satellite (non-centralized or regional) cancer centers nization of national medical breast health groups

Level of resources	Public Education and Awareness	Detection Methods
Basic	Development of outurally sensitive, inguistically appropriate local education programs for target populations to teach value of early detection, hereat cancer risk factors and breast health awareness (education + self-examination)	Clinical history and CBE
Limited	Culturally and linguistically appropriate targeted outreachieducation encouraging CBE for age groups at higher risk administered at district/provincial level using healthcare providers in the field	Disgnostic breast US +/- diagnostic mammography in women with positive CBE Mammographic screening of target group?
Enhanced	Regional awareness programs regarding breast health linked to general health and women's health programs	Mammographio screening every 2 years in women ages 50-69° Consider mammographic screening every 12-18 months in women ages 40-49°
Maximal	National awareness campaigns regarding breast health using media	Consider annual mammographic screening in women ages 40 and older Other imaging technologies as appropriate for high-risk groups†

DIAGNOSIS

Level of resources	Clinical	Imaging and Lab Tests	Pathology
Basic	History Physical examination Clinical breast examination (CBE) Tissue axampilo for cancer diagnosis (systologic or histologic) prior to initiation of treatment		Pathology diagnoss obtained for every treast lice to yary available sampling procedure appropriate diagnostic and proposition effortie informatic and proposition effortie informatic and proposition yare and tumor practice yare and tumor practice process to establish homone receptor status possibly including empiric assessment of recorrison to the indey fun- torial practice and proposition to the practice and practice and the practice and
Limited	US-guided FNAB of sonographically suspicious axillary nodes Sentinel lymph node (SLN) biopsy with blue dye‡	Diagnostic breast ultrasound (US) Plain chest and skeletal radiography Liver US Blood chemistry profile* Complete blood count (CBC)*	Determination of ER status by IHC† Determination of margin status, DCIS content, presence of LVI Frozen section or louch prep SLV analysis §
Enhanced	Image guided breast sampling Preoperative needle localization under mammo andler US guidance SLN biopsy using radiotracer‡	Diagnostic mammography Specimen radiography Bone scart, CT scan Cardiac function monitoring	Measurement of HER-2/neu overexpression or gene amplification§ Determination of PR status by IHC
Maximal		PET scan. MBI scan. breast MRI, BRCA1/2 testing Mammographic double reading	IHC staining of sentinel nodes for cytokeratin to detect micrometastases Pathology double reading Gene profiling tests

STAGE I

Level of	Local-Region	nal Treatment	Systemic Treatment (Adjuvant)			
resources	Surgery	Radiation Therapy	Chemotherapy	Endocrine Therapy	Biological Therapy	
Basic	Modified radical mastectomy			Oophorectomy in premenopausal women Tamoxifen*		
Limited	Breast conserving surgery† Sentinel lymph node (SLN) biopsy with blue dye‡		Classical CMF§ AC, EC, or FAC§			
Enhanced	SLN biopsy using radiotracer‡ Breast reconstruction surgery	Breast- conserving whole-breast irradiation as part of breast- conserving therapy†	Taxanes	Aromatase inhibitors LH-RH agonists	Trastuzumab fo treating HER-2/ neu positive disease!	
Maximal			Growth factors Dose-dense chemotherapy			

STAGE II

Level of	Local-Regional Treatment		Systemic Treatment (Adjuvant)			
resources	Surgery	Radiation Therapy	Chemotherapy	Endocrine Therapy	Biological Therapy	
Basic	Modified radical mastectomy	x	Classical CMF† AC, EC, or FAC†	Oophorectomy in premenopausal women Tamoxifen‡		
Limited	Breast conserving surgery§ Sentinel lymph node (SLN) biopsy with blue dye ^l	Postmastectomy irradiation of chest wall and regional nodes for high-risk cases'			٢	
Enhanced	SLN biopsy using radiotracer† Breast reconstruction surgery	Breast- conserving whole-breast irradiation as part of breast- conserving therapy§	Taxanes	Aromatase inhibitors LH-RH agonists	Trastuzumab for treating HER-2/ neu positive disease ¹	
Maximal			Growth factors Dose-dense chemotherapy			

LOCALLY ADVANCED

Level of	Local-Regio	nal Treatment					Level of	
resources Basic	Streary Modified radical mastectomy	Radiation Therapy	Preoperative chemotherapy with AC, EC, FAC or CMF†	Endocrine Theopy Oophorectomy in premenopausal women Tamoxifen‡	Biological Therapy		Basic	Tota fo br a c
Limited		Postmastectomy irradiation of chest wall and regional nodes*			ŝ		Limited	
Enhanced	Breast- conserving surgery Breast reconstruction surgery	Breast- conserving whole-breast irradiation as part of breast- conserving therapy	Taxanes	Aromatase inhibitors LH-RH agonists	Trastuzumab for treating HER-2/ neu positive disease§	renc	Enhanced	
Maximal			Growth factors Dose-dense chemotherapy				Maximal	
							L	_

METASTATIC

	Level of	Local-Regional Treatment		Systemic Treatment (Palliative)			
	resources	Surgery	Radiation Therapy	Chemotherapy	Endocrine Therapy	Supportive Therapy	
	Basic	Total mastectomy for ipsilateral breast tumor recurrence after breast conserving surgery*			Oophorectomy in premenopausal women Tamoxifen†	Nonopioid and opioid analgesics and symptom management	
	Limited		Palliative radiation therapy	Classical CMF‡ Anthracycline monotherapy or in combination‡			
enc	Enhanced			Sequential single agent or combination chemotherapy Trastuzumab Lapatinib	Aromatase inhibitors	Bisphosphonates	0
	Maximal			Bevacizumab	Fulvestrant	Growth factors	
	L				° 1		

BREAST HEALTH GLOBAL INITIATIVE: 5-Year Implementation Plan

- Dissemination & implementation (D&I)
 research
- Education and training programs
- Technology application and
- development



Conclusion

 The BHGI example could be a model to analyze in future discussions for a common World Platform for Breast Centers and Units Accreditation





Role of leading organizations





Role of leading organizations

SIS (Senologic International Society), EUSOMA (European **Society of Breast Cancer Specialists) and NAPBC (National Accreditation Program for Breast Centers) can provide technical** support and experience in the process of accreditation of breast centers and units.





Future possible actions





Possible strategy

- Development of a model
- Support and technical advice from leading organizations
- International support for the implementation of accreditation in different regions of the world





Development of a model

- 1. A stepwise process
- 2. Stimulate breast groups and centers to apply for the accreditation
- 3. If the applicant institution do not fulfill all the requirements, a mentor organization will support and advise during the application process
- 4. National and international organizations together with local institutions will collaborate with the applicant institution





International Organizations

- It would be possible to request advice and endorsement from international organizations.
- WHO, PAHO, IAEA, IARC and others have this type of projects in the agendas
- UICC would facilitate contacts and suggest initiatives and partnerships
- Network of NCI's in Europe and LatinAmerica (RINC)





UICC World Cancer Declaration



 The World Cancer Declaration is a tool to help bring the growing cancer crisis to the attention of government leaders and health policymakers in order to significantly reduce the global cancer burden by 2020.





UICC World Cancer Declaration



 The Declaration calls on the world to take immediate steps to reduce the global cancer burden by committing to the 11 Declaration targets and providing resources and political backing for the priority actions need to achieve them.





World Cancer Declaration- Targets

- 1. Sustainable delivery systems will be in place to ensure that effective cancer control programmes are available in all countries
- 2. The measurement of the global cancer burden and the impact of cancer control interventions will have improved significantly
- 3. Global tobacco consumption, obesity and alcohol intake levels will have fallen significantly
- 4. Populations in the areas affected by HPV and HBV will be covered by universal vaccination programmes





World Cancer Declaration Targets 2

- 5- Public attitudes towards cancer will improve and damaging myths and misconceptions about the disease will be dispelled,
- 6- Many more cancers will be diagnosed when still localized through the provision of screening and early detection programmes and high levels of public and professional awareness about important cancer warning signs,
- 7- Access to accurate cancer diagnosis, appropriate cancer treatments, supportive care, rehabilitation services and palliative care will have improved for all patients worldwide,





World Cancer Declaration Targets 3

- 8- Effective pain control measures will be available universally to all cancer patients in pain,
- 9- The number of training opportunities available for health professionals in different aspects of cancer control will have improved significantly
- 10- Emigration of health workers with specialist training in cancer control will have reduced dramatically
- 11- There will be major improvements in cancer survival rates in all countries.





UICC role



- The initiative of a common World Platform for Breast Centers/Units Accreditation is an important initiative
- It follows closely several of the targets of the WCD
- UICC would endorse and facilitate the development and implementation of this proposal





Thank you very much for your attention.



